Evaluation of Ixazomib, Lenalidomide, Dexamethasone in Newly Diagnosed Multiple Myeloma Patients eligible for High Dose Therapy
- Registry ID
- EUCTR2014-003467-37
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- CHU de Toulouse
- Start date
- 2015-06-23
- Completion date
- 2020-09-24
- Last update
- 2026-08-16
Conditions
- Multiple Myeloma newly diagnosed
Summary
Evaluate the sCR rate of the combination of Ixazomib, Lenalidomide with and without dexamethasone as induction and extended consolidation therapy in an intensive program in newly diagnosed MM patients, after consolidation and before maintenance therapy.
Locations
View on source registry